Effects of chronic infusion of neurotensin and a neurotensin NT1 selective analogue PD149163 on amphetamine-induced hyperlocomotion

Journal of Psychopharmacology

Volumn 22, Issue 3, 2008, Pages 300-307

  Norman, C ^a   Beckett, S R G ^b   Spicer, C H ^b   Ashton, D ^c   Langlois, X ^c   Bennett, G W ^b  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Amphetamine; Antipsychotic; Chronic; Locomotion; Rat; Schizophrenia

Indexed keywords

AMPHETAMINE; NEUROTENSIN; NEUROTENSIN DERIVATIVE; NEUROTENSIN RECEPTOR; PD 149163;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; INJECTION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT DURATION;

AMPHETAMINE; ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG SYNERGISM; INJECTIONS, INTRAVENTRICULAR; MALE; MOTOR ACTIVITY; NEUROTENSIN; RADIOIMMUNOASSAY; RATS; RECEPTORS, NEUROTENSIN;

EID: 45349104179     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107083838     Document Type: Article

References (39)

1. Arnt, J. (1995) Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol 283: 55-62.
2. Binder, EB, Gross, RE, Nemeroff, CB, Kilts, CD (2002) Effects of NT receptor antagonism on latent inhibition in Sprague-Dawley rats. Psychopharmacology 161: 288A - 295A.
3. Binder, EB, Kinkead, B., Owens, MJ, Nemeroff, CB (2000) The role of NT in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Biol Psychiatry 50: 856-872.
4. Binder, EB, Kinkead, B., Owens, MJ, Nemeroff, CB (2001) Neurotensin and dopamine interactions. Pharmacol Rev 53: 453-486.
5. Bissette, G., Nemeroff, CB, Loosen, PT, Prange, AJ, Lipton, MA (1976) Hypothermia and intolerance to cold induced administration of the hypothalamic peptide NT. Nature 262: 607-609.
6. Boules, M., McMahon, B., Wang, R., Warrington, L., Stewart, J., Yerbury, S., Faug, A., McCormack, D., Richelson, E. (2003) Selective tolerance to the hypothermic effects of a NT analog that crosses the blood-brain barrier. Brain Res 987: 39-48.
7. Boules, M., Warrington, L., Fauq, A., McCormick, D., Richelson, E. (2001) A novel NT analog blocks cocaine and D-amphetamine-induced hyperactivity. Eur J Pharmacol 426: 73-76.
8. Caceda, R., Kinkead, B., Owens, MJ, Nemeroff, CB (2005) Virally mediated increased NT 1 receptor in the nucleus accumbens decreases behavioral effects of mesolimbic system activation. J Neurosci 25: 11748-11756.
9. Carraway, R., Leeman, SE (1973) The isolation of a new hypotensive peptide, NT, from bovine hypothalami. J Biol Chem 248: 6854-6861.
10. Clineschmidt, BV, McGuffin, JC, Bunting, PB (1979) Neurotensin: antinocisponsive action in rodents. Eur J Pharmacol 54: 129-139.
11. Donatodi Paola, E., Cusack, B., Yamada, M., Richelson, E. (1993) Desensitization and down-regulation of NT receptors in murine neuroblastoma clone N1E-115 by [D-Lys8] NT (8-13). J Pharmacol Exp Ther 264: 1-5.
12. Ervin, GN, Birkemo, LS, Nemeroff, CB, Prange, AJ (1981) Neurotensin blocks certain amphetamine induced behaviours. Nature 291: 73-76.
13. Feifel, D., Minor, KL, Dulawa, S., Swerdlow, NR (1997 a) The effects of intra-accumbens NT on sensorimotor gating. Brain Res 760: 80-84.
14. Feifel, D., Reza, TL, Roebeck, SL (1997 b) Pro-dopaminergic effects of NT on sensori motor gating deficits. Peptides 18: 1457-1460.
15. Feifel, D., Reza, TL, Wustrow, DJ, Davis, MD (1999) Novel antipsychotic-like effects on pre-pulse inhibition of startle produced by a NT agonist. J Pharmacol Exp Ther 288: 710-713.
16. Hadden, MK, Orwig, KS, Kokko, KP, Mazella, J., Dix, TA (2005) Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable NT (8-13) analogues containing non-natural arginine and lysine residues. Neuropharmacology 49: 1149-1159.
17. Hermans, E., Vanisberg, MA, Geurts, M., Maloteaux, M. (1997) Down-regulation of NT receptors after ligand-induced internalization in rat primary cultured neurons. Neurochem Int 31: 291-299.
18. Hertel, P., Byskov, L., Didriksen, M., Arnt, J. (2001). Induction of tolerance to the suppressant effect of NT analog NT69L on amphetamine-induced hyperactivity. Eur J Pharmacol 422: 77-81.
19. Hertel, P., Olsen, CK, Didriksen, M., Arnt, J. (2002) Repeated administration of the NT analogue NT69L induces tolerance to its suppressant effect on conditioned avoidance behaviour. Eur J Pharmacol 439: 107-111.
20. Holtom, PE, Needham, PL, Bennett, GW, Aspley, S. (2000 a) Neurotensin: controversial findings on its neuromodulatory role in the mesolimbic dopamine system. Schizophr Res 41: 239-239.
21. Holtom, PE, Wasuntararawat, C., Moss, SH, Aspley, S., Needham, PL, Bennett, GW (2000 b). A highly sensitive and selective radioimmunoassay for the measurement of NT. J Neurosci Methods 100: 151-156.
22. Jolicoeur, FB, Barbeau, A., Rioux, F., Quirion, R., St-Pierre, S. (1981). Differential neurobehavioral effects of NT and structural analogues. Peptides 2: 171-175.
23. Kinkead, B., Shahid, S., Owens, M., Nemeroff, CB (2000) Effects of acute and subchronic administration of typical and atypical antipyschotic drugs on the NT system of the rat brain. J Pharmacol Exp Ther 295: 67-73.
24. Kitabi, P., De Nadai, F., Labbe-Jullie, C., Dubuc, I., Nouel, D., Costentin, J., Masuo, Y., Rostene, W., Woulfe, J., Lafortune, L. (1992) Functional and pharmacological aspects of central neuropeptidergic transmission mediated by NT and neuromedin. Clin Neuropharmacol 15 (Suppl. 1A, 11). 313A - 314A.
25. Lambert, PD, Gross, R., Nemeroff, CB, Kilts, CD (1995) Anatomy and mechanisms of NT-dopamine interactions in the central nervous system. Ann NY Acad Sci 757: 377-389.
26. Leonetti, M., Brun, P., Clerget, M., Steinberg, R., Soubrie, P., Renaud, B., Suaud-Chagny, MF (2004) Specific involvement of NT type 1 receptor in the NT-mediated in vivo dopamine efflux using knockout mice. J Neurochem 89: 1-6.
27. Lindstrom, LH, Widerlov, E., Bissette, G., Nemeroff, CB (1988) Reduced CSF NT concentration in drug free schizophrenic patients. Schizophr Res 1: 55-59.
28. Ljungberg, T., Ungerstedt, U. (1976) Automatic registration of behaviour related to dopamine and noradrenaline transmission. Eur J Pharmacol 36: 181-188.
29. Nemeroff, CB (1980) Neurotensin: perchance and endogenous neuroleptic ? Biol Psychiatry 15: 283-302.
30. Nemeroff, CB, Luttinger, DE, Hernadnez, RB (1983) Interactions of NT with brain dopamine systems: biochemical and behavioral Studies. J Pharmacol Exp Ther 225: 337-345.
31. Norman, C., Beckett, SRG, Roe, CH, Ashton, D., Nayak, S., Bennett, GW (2004) Reciprocal effects of acute versus chronic central administration of NT on amphetamine hyperactivity. J Psychopharmacol 18: A56 - A56.
32. Norman, C., Beckett, SRG, Spicer, CH, Ashton, D., Langlois, X., Bennett, GW (2005) Effects of NT and NT analogues on amphetamine-induced hyperlocomotion; antipsychotic or psychotomimetic? J Psychopharmacol 19 (Suppl.). A30 - A30.
33. Petrie, KA, Bubser, M., Casey, CD, Davis, MD, Roth, BL, Deutch, AY (2004) The NT agonist PD 149163 increases Fos expression in the prefrontal cortex of the rat. Neuropsychopharmacology 29: 1878-1888.
34. Robinson, TE, Becker, JB (1986) Enduring changes in brain and behaviour produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 11: 157-198.
35. Rompré, PP (1997) Repeated activation of NT receptors sensitises to the stimulant effect of amphetamine. Eur J Pharmacol 328: 131-134.
36. Rostene, W., Brouard, A., Dana, C., Masuo, Y., Agid, F., Vial, M., Lhiaubet, AM, Pelaprat, D. (1992) Interaction between NT and dopamine in the brain. Morphofunctional and clinical evidence. Ann NY Acad Sci 668: 365-367.
37. Sharma, RP, Janicak, PG, Bissette, G., Nemeroff, CB (1997) CSF NT concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Am J Psychiatry 29: 1019-1021.
38. Shilling, PD, Richelson, E., Feifel, D. (2003) The effects of systemic NT69L, a NT agonist on baseline and drug-disrupted prepulse inhibition. Behav Brain Res 143: 7-14.
39. Wustrow, DJ, Davies, MD, Akunne, HC, Corbin, AE, Wiley, JN, Wise, LD, Heffner, TG (1995) Reduced amide bond NT 8-13 mimetics with potent in vivo activity. Bioorg Med Chem Lett 5: 999-1002.